Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372942 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL378835 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL2208136 | 0.85 | CYP1A2 (0.54) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL6998732 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL10569602 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| Acetamide SCHEMBL11005368 | 0.81 | MAPT (0.53) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL7782499 | 0.81 | CES1 (0.52) | CYP1A2MAPTKMT2AKCNN4CYP2C19 | |
| SCHEMBL12083438 | 0.79 | KCNN4 (0.60) | MAPTKMT2AKCNN4HDAC3HDAC4 | |
| Methylamine SCHEMBL11005397 | 0.78 | MAPT (0.55) | CYP1A2CYP2D6MAPTKMT2AKCNN4 | |
| SCHEMBL10810428 | 0.78 | HDAC3 (0.43) | CYP1A2CYP2D6MAPTKMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022126942-A1 | SYNTHESIS METHOD FOR CYCLOPROPYL-CONTAINING CHIRAL AMINE HYDROCHLORIDE | 诚达药业股份有限公司 | 2022-06-23 | — | — | WO | claimed |
| US-8440834-B2 | 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | claimed |
| US-20130012487-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-01-10 | — | — | US | claimed |
| EP-2393782-B1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2012-09-12 | — | — | EP | claimed |
| EP-2393782-A1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2011-12-14 | — | — | EP | claimed |
| WO-2011117885-A1 | PROCESS FOR PREPARATION OF ENANTIOMERS OF LICARBAZEPINE | INTAS PHARMACEUTICALS LIMITED (IN) | 2011-09-29 | — | — | WO | claimed |
| WO-2010089107-A1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-08-12 | — | — | WO | claimed |
| US-20100204256-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-08-12 | — | — | US | claimed |
| EP-2216327-A1 | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-08-11 | — | — | EP | claimed |
| US-20220218678-A1 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-07-14 | — | — | US | disclosed |
| WO-2022126942-A1 | SYNTHESIS METHOD FOR CYCLOPROPYL-CONTAINING CHIRAL AMINE HYDROCHLORIDE | 诚达药业股份有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-112552184-B | Synthetic method of cyclopropyl-containing chiral amine hydrochloride | 诚达药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210038575-A1 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-02-11 | — | — | US | disclosed |
| EP-3732164-A1 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS | Chiesi Farmaceutici S.p.A. (IT) | 2020-11-04 | — | — | EP | disclosed |
| EP-2393782-B1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2012-09-12 | — | — | EP | disclosed |
| EP-2393782-A1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011117885-A1 | PROCESS FOR PREPARATION OF ENANTIOMERS OF LICARBAZEPINE | INTAS PHARMACEUTICALS LIMITED (IN) | 2011-09-29 | — | — | WO | disclosed |
| WO-2010089107-A1 | BENZOIC ACID (1-PHENYL-2-PYRIDIN-4-YL) ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204256-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-08-12 | — | — | US | disclosed |
| EP-2216327-A1 | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204256-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | CYP1A2 165/4885CYP2D6 1181/4885MAPT 3475/4885 |
| US-20210038575-A1 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS | CFTR, CLIC1, CLCN2 | CYP1A2 401/4885CYP2D6 2068/4885MAPT 4815/4885 |
| US-20130012487-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | CYP1A2 165/4885CYP2D6 1181/4885MAPT 3475/4885 |
| US-20220218678-A1 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS | CFTR, CLIC1, CLCN2 | CYP1A2 401/4885CYP2D6 2068/4885MAPT 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.